P17.83 OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB AT A TERTIARY CARE CENTER

BACKGROUND: Bevacizumab is FDA approved for use in recurrent glioblastoma (rGBM). There is limited information on outcomes of rGBM treated with bevacizumab at tertiary care hospitals. We evaluated the progression-free survival (PFS) and overall survival (OS) in rGBM patients treated with bevacizumab...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Stevens, G.H.J., Sakruti, S., Griffin, S., Peereboom, D., Ahluwalia, M.S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2014
Gaiak:
Poster Presentations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185786/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.412
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak